MENU
+Compare
HRTS
ETF ticker: NASDAQ
AS OF
Jan 14, 04:13 PM (EDT)
Price
$36.24
Change
+$0.34 (+0.95%)
Net Assets
56M

HRTS stock forecast, quote, news & analysis

The investment seeks to provide long-term growth of capital... Show more

Category: #Health
HRTS
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for HRTS with price predictions
Jan 13, 2026

HRTS in downward trend: price may drop because broke its higher Bollinger Band on January 07, 2026

HRTS broke above its upper Bollinger Band on January 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 18 similar instances where the stock broke above the upper band. In of the 18 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for HRTS moved out of overbought territory on January 08, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 16 similar instances where the indicator moved out of overbought territory. In of the 16 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 30 cases where HRTS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for HRTS turned negative on January 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 24 similar instances when the indicator turned negative. In of the 24 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRTS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 19, 2025. You may want to consider a long position or call options on HRTS as a result. In of 32 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HRTS advanced for three days, in of 140 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 93 cases where HRTS Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), ABBVIE (NYSE:ABBV), Unitedhealth Group (NYSE:UNH), AstraZeneca PLC (NASDAQ:AZN), Merck & Co (NYSE:MRK), Abbott Laboratories (NYSE:ABT), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Boston Scientific Corp (NYSE:BSX), Medtronic plc (NYSE:MDT).

Industry description

The investment seeks to provide long-term growth of capital. Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from products or services related to GLP-1 and the treatment of cardiovascular diseases and/or metabolic diseases, as defined by the Centers for Diseases Control and Preventions. The fund generally is expected to consist of more than 15 companies but not more than 100 companies. The fund is non-diversified.

Market Cap

The average market capitalization across the Tema Heart & Health ETF ETF is 106.57B. The market cap for tickers in the group ranges from 3.51M to 964.11B. LLY holds the highest valuation in this group at 964.11B. The lowest valued company is NOVN at 3.51M.

High and low price notable news

The average weekly price growth across all stocks in the Tema Heart & Health ETF ETF was 72%. For the same ETF, the average monthly price growth was 41%, and the average quarterly price growth was 337%. MREO experienced the highest price growth at 74%, while MDGL experienced the biggest fall at -11%.

Volume

The average weekly volume growth across all stocks in the Tema Heart & Health ETF ETF was -7%. For the same stocks of the ETF, the average monthly volume growth was 8% and the average quarterly volume growth was -1%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 68
Price Growth Rating: 45
SMR Rating: 70
Profit Risk Rating: 64
Seasonality Score: -6 (-100 ... +100)
View a ticker or compare two or three
HRTS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
United Satets
Phone
N/A
Web
www.tema.co